0001193125-26-212146
SEC filingJanux reported first revenue of $3.7M from BMS collaboration versus none last year, narrowing operating loss 2.0% to -$34.2M despite rising R&D and G&A expenses, though net loss widened 3.6% to -$24.4M due to lower interest income.
Janux Therapeutics generated its first quarterly revenue of $3.7 million in Q1 FY2026, up from zero in the prior year, primarily from the new BMS collaboration. This milestone reflects progress in partnership-driven income as the company advances its clinical pipeline without product sales yet. Operating income improved slightly by 2.0% to -$34.2 million from -$34.9 million year-over-year. The narrower loss stems from interest income partially offsetting expense growth, though operating margin remained deeply negative at -916.5% given the early revenue base relative to high R&D costs.
Looking forward, prior and expected future losses continue adversely affecting stockholders' equity and working capital. Uncertainties around potential collaborations for product candidates add variability to development timelines and capital requirements, as arrangements remain unpredictable in timing and scope.